Aquestive Therapeutics (NASDAQ:AQST) Lowered to Sell Rating by Wall Street Zen

Aquestive Therapeutics (NASDAQ:AQST) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research firms have also recently commented on AQST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Piper Sandler lifted their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. JMP Securities boosted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a research report on Thursday, October 9th. Finally, Zacks Research raised shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $8.83.

Aquestive Therapeutics Trading Down 6.6%

NASDAQ:AQST opened at $2.95 on Friday. The company has a market cap of $359.90 million, a P/E ratio of -4.15 and a beta of 1.66. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $7.55. The company’s 50-day moving average price is $5.26 and its 200-day moving average price is $5.20.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $12.81 million for the quarter, compared to the consensus estimate of $12.94 million. On average, analysts expect that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AQST. Pictet Asset Management Holding SA acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at about $94,000. Arizona State Retirement System acquired a new position in shares of Aquestive Therapeutics in the 4th quarter worth approximately $184,000. Arcataur Capital Management LLC purchased a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $239,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Aquestive Therapeutics in the 4th quarter valued at approximately $420,000. Finally, MBM Wealth Consultants LLC acquired a new stake in Aquestive Therapeutics in the 4th quarter valued at approximately $109,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.